CTNNA3 and Alzheimer disease: The gene expression studies from the in-vitro LRRTM3 knock-down model and human brains, reveal complex correlations between mRNA levels of LRRTM3, CTNNA3, APP and BACE1. These gene and protein interactions may ultimately influence APP metabolism and AD risk.